Send me real-time posts from this site at my email

Watchlist Update: 5-9-2019 - IMMU - Immunomedics - Analyst Comments

Immunomedics analyst commentary at Piper Jaffray

Immunomedics refiling timeline should bring some relief, says Piper Jaffray. Immunomedics indicated that it is now in broad alignment with the FDA around the issues raised in the Complete Response Letter and is projecting a biologics license application resubmission for sacituzumab to occur in early Q4, Piper Jaffray analyst Joseph Catanzaro tells investors in a post-earnings research note. The analyst believes this timeline is largely in-line with consensus and should provide a "bit of relief." Investors may still have some questions around the Ascent trial timing, but given the FDA's apparent comfort with the clinical data, a further approval delay is unlikely given the extreme unmet need in triple-negative breast cancer, adds the analyst. He maintains an Overweight rating on Immunomedics with a $20 price target.

Read more at:  (source)

Tiger's Take:    $IMMU

On our trading list, a biotech with good potential.

$IMMU, Immunomedics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or comments.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue